Scott Dreyer: Yes, I think you hit it, Joe. The only other thing I’d add is a reminder that the biggest feeder pool to the growth of both Xtampza and BELBUCA is the IR to ER transition in the IR market, which is still very large, with many patients being treated for their pain. So there’s tremendous opportunity for us to grow.
Brandon Folkes: Thanks very much. That’s actually going to be my follow up, and you kind of touched on it. But do you expect that feeder pool to change or evolve at all over the coming years and the asset for me, thank you very much.
Joe Ciaffoni: No, I don’t think we anticipate any changes in the dynamic portion of the market.
Brandon Folkes: Great, thanks for progress.
Joe Ciaffoni: Thank you.
Operator: Our next question comes from Serge Belanger with Needham & Company. Please state your question.
Serge Belanger: Hi, a couple of questions for us. First of all, maybe it’s unknown on recent market dynamics. I think one of them headwinds for most of 2022 was a kind of a slower pace of office visits that led to an unfavorable business mix. Just curious if that has changed over the fourth quarter. And in the early — front, you kind of had the boxes that you’re looking to take off as you look for assets. But in terms of therapeutic areas that you’re targeting, should we still expect that you could do a third transaction in the pain space? Are they still assets remaining that pick off those categories that you talked about? Thanks.
Joe Ciaffoni: Yes. Hey, Serge, if you could do me a favor and I apologize for this, you were you were coming in and out and I’m not sure we clearly got your two questions. So if you wouldn’t mind repeating them.
Serge Belanger: Sure. I’ll start with the first one. Is this better?
Joe Ciaffoni: Yes.
Serge Belanger: Okay so the first one was about the recent market dynamics. One of the headwinds in 2022 was the pace, a slower pace of office visits leading to an unfavorable business mix, cause if that has improved and whether an improvement is embedded in the guidance and in plans to grow Xtampza and BELBUCA.
Joe Ciaffoni: Okay, Scott, will take that.
Scott Dreyer: Yes, thanks Serge. So, so look, since the last time we talked, I mean no, we haven’t seen an improvement in terms of patients returns. But I think what’s important is, that’s just the market we play. And sort of your question around guidance, no, our guidance doesn’t contemplate any type of return of the market, right? We just view it as now this is the market we play in. And really from a focus standpoint, but we’re not focused on the external factors like that, that we can’t control. We’re focused on the internal factors and that’s around commercial execution of our people and changing behaviors. So that’s where our focus is, and we’ll keep monitoring what happens externally.
Serge Belanger: Okay. And the question on BD, the second question was talking.
Joe Ciaffoni: Well Serge you just broke out again.
Serge Belanger:
Operator: Sir, could you pick up your handset? Maybe we’ll get a better sound that way.
Operator: Okay, we’re going to move on to the next question. Mr. Belanger. Thank you. Our next question comes from Greg Fraser with Truist. Please, state your question.
Greg Fraser: Hey, guys, thanks for taking the questions. Hopefully you can hear me okay. When do you believe your commercial initiatives behind Xtampza could return the price to positive year-over-year prescription growth? You mentioned gross to the full year for the Xtampza and BELBUCA. Curious, how long? Or how quickly do you think you can get back the positive growth for prescriptions?
